Key result
Midodrine has been demonstrated to be effective and safe in the acute and chronic treatment of haemodialysis-associated hypotension in end stage renal disease patients.
Why the study?
Does midodrine reduce the severity and frequency of hypotensive episodes in end stage renal disease patients on haemodialysis?
Does midodrine reduce the severity and frequency of hypotensive episodes in end stage renal disease patients on haemodialysis?
Midodrine is considered an effective and safe pharmacological option for managing acute and chronic dialysis-associated hypotension.
No takes yet. Share an insight, caveat, or question.
May support midodrine for dialysis hypotension in ESRD; leaves open need for RCTs to confirm efficacy and safety.
Mark A. Perazella (2003) conducted a review in Dialysis-associated hypotension in end stage renal disease. Midodrine was evaluated. Midodrine has been demonstrated to be effective and safe in the acute and chronic treatment of haemodialysis-associated hypotension in end stage renal disease patients.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: